Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Monday, December 14, 2020
Samsung Biologics officially began construction of its Plant 4 in Incheon, South Korea.
read more
Tuesday, November 28, 2023
Samsung Biologics, a prominent global contract development and manufacturing organization (CDMO), hosted its inaugural Suppliers ESG Day at its Songdo headquarters and online, marking a significant step toward sharing environmental, social, and ...
read more
Samsung Biologics announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company’s first manufacturing presence in the United States.
read more
Monday, February 24, 2020
Samsung Biologics has been monitoring the COVID-19 situation closely since the initial outbreak in late January and taking proactive measures company-wide to ensure a safe working environment and continuous business operations.
read more
Thursday, November 05, 2026
Samsung Biologics has achieved a 'Negligible Risk' rating in the latest Morningstar Sustainalytics ESG Risk Ratings assessment. The CDMO received an ESG Risk Rating score of 9.0, advancing from its previous 'Low Risk' rating to 'Negligible Risk,' the...
read more
Samsung BioLogics has successfully performed N-1 (3,000L) perfusion with Alternating Tangential Flow device to supply the 15,000L commercial production process in the Plant 3 facility at its manufacturing site in Songdo, S. Korea.
read more
Samsung Biologics, a contract development and manufacturing organization (CMDO), celebrated the one-year mark of Live Virtual Tour (LVT), a platform to provide remote site inspections for clients and regulatory agencies. The tool was developed and ...
read more
Samsung Biologics, a world-leading contract development and manufacturing organization (CDMO), is launching its new proprietary development technology platforms – S-DUAL™ and DEVELOPICK™ – at this year's BioProcess International Conference and ...
read more
Tuesday, September 01, 2026
Samsung Biologics has published the formal prospectus for its planned acquisition of PolyPeptide Group AG, offering about $55.70 in cash per share in a transaction that values the Swiss peptide manufacturer’s equity at approximately $1.83 billion.
read more
Samsung Biologics has announced an all-cash public tender offer to acquire PolyPeptide Group AG, valuing the peptide-focused contract development and manufacturing organization at approximately CHF 1.46 billion.
read more
Wednesday, December 30, 2020
Samsung Biologics announced John Rim as its President and CEO.
read more
Samsung Biologics has successfully renewed its ISO 27001 certification (Information Security Management System) and obtained ISO 27017 certification (Information Security in cloud services) and ISO 37001 certification (Anti-bribery management systems...
read more
Samsung BioLogics announced on October 1st, 2018 that its Plant 3 has become cGMP ready and started production (OOF, out of freezing) after its successful validation.
read more
Samsung Biologics signed an agreement with the Incheon Free Economic Zone (IFEZ) on July 18th to build out its second Bio Campus.
read more
Samsung BioLogics announced today that a third monoclonal antibody Drug Substance has been licensed by the FDA for its second plant.
read more